What is the ROE (Return on Equity) of Pharmaust this year?
The ROE of Pharmaust this year is -1.6 undefined.
Pharmaust ROE 2024
Pharmaust ROE
-1.6
Ticker
PAA.AX
ISIN
AU000000PAA1
WKN
A0DNJ3
In 2024, Pharmaust's return on equity (ROE) was -1.6, a 633.44% increase from the -0.22 ROE in the previous year.
Pharmaust Aktienanalyse
What does Pharmaust do?
Pharmaust Ltd is a biotechnology company based in Perth, Australia. The company was founded in 2001 by Dr. Roger Aston and Dr. Paul Gavin as a spin-off from the School of Biomedical Sciences at Curtin University of Technology. Their goal was to advance the discovery and development of novel therapeutics and diagnostics for cancer and autoimmune diseases. Pharmaust's history began with the discovery of a novel molecule called PPL-1 by Dr. Roger Aston. This molecule had the potential to serve as a cancer therapeutic as it could inhibit the release of tumor cells. Pharmaust researchers held patents for PPL-1 in the US, Europe, and Australia. Another important milestone for Pharmaust was the discovery of a new class of compounds with potential cancer and autoimmune therapeutics known as PPL-100, PPL-300, and PPL-400. Pharmaust's business model is focused on bringing novel drugs and diagnostics to market and selling them. Pharmaust aims to use its technologies to reduce the high costs of drug research and ultimately help patients suffering from serious diseases. Pharmaust has several divisions, including: - Pharmaceutical research and development: Pharmaust is working to discover and develop new therapeutics and diagnostics, particularly for the treatment of cancer and autoimmune diseases. - Clinical research: Pharmaust conducts clinical trials to assess the safety and efficacy of its drugs and obtain the necessary approvals for market authorization. - Licensing and marketing: Pharmaust markets its products in Australia and other countries, and licenses its technologies to other biopharmaceutical companies to generate additional revenue. Pharmaust's current product portfolio includes two main products sold under the brand names Monepantel and PPL-003. Monepantel is an anthelmintic used to treat parasite infestation in livestock such as sheep and goats. PPL-003 is an immunotherapy for the treatment of skin cancer, currently being tested in clinical trials. In particular, Pharmaust has developed a therapy in recent years that supports immunotherapy and works closely with clinics and payers to further develop and market their therapy. Pharmaust has received numerous awards and recognitions in recent years, including the award for Perth's Best Emerging Company and recognition from the Western Australian Industry and Export Awards (WAIEA) and the Australasian Society for Stem Cell Research (ASSCR). In conclusion, Pharmaust Ltd remains committed to saving and improving lives. The company sees a promising future in the discovery, development, and marketing of novel therapeutics and diagnostics for the treatment of serious diseases. By integrating four different drug classes, Pharmaust is working on a range of early-stage development projects that have the potential to help patients suffering from various diseases. Pharmaust ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Pharmaust's Return on Equity (ROE)
Pharmaust's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Pharmaust's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Pharmaust's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Pharmaust’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Pharmaust stock
How has the Return on Equity (ROE) of Pharmaust developed compared to the previous year?
The ROE of Pharmaust has increased by 633.44% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Pharmaust?
A high ROE indicates that Pharmaust generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Pharmaust?
A low ROE can indicate that Pharmaust is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Pharmaust affect the company?
A change in ROE (Return on Equity) of Pharmaust can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Pharmaust?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Pharmaust?
Some factors that can influence Pharmaust's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Pharmaust pay?
Over the past 12 months, Pharmaust paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharmaust is expected to pay a dividend of 0 AUD.
What is the dividend yield of Pharmaust?
The current dividend yield of Pharmaust is .
When does Pharmaust pay dividends?
Pharmaust pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Pharmaust?
Pharmaust paid dividends every year for the past 0 years.
What is the dividend of Pharmaust?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Pharmaust located?
Pharmaust is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharmaust kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharmaust from 9/10/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Pharmaust pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Pharmaust in the year 2023?
In the year 2023, Pharmaust distributed 0 AUD as dividends.
In which currency does Pharmaust pay out the dividend?
The dividends of Pharmaust are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Pharmaust
Our stock analysis for Pharmaust Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmaust Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
